Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 ...

The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...

A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.

The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ ...